Search Clinical Trials
Completed
Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE) (External Link)
Blood has been previously taken from the patient and the donor to make the cells. To make the special cell line, special blood cells called dendritic cells (DCs)were made first …
Baylor Role:
Lead Sponsor
Completed
Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) (External Link)
Patients may be screened for study entry when they have persistent disease despite standard therapy as defined in the inclusion criteria. At that stage a search will be done of …
Baylor Role:
Lead Sponsor
Completed
EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC) (External Link)
Three different doses of CTL will be evaluated: dose level I: 2 x 10e7/m2; dose level II: 5 x 10e7/m2; dose level III: 1 x 10e8/m2 Day 1 YTH 24/54 …
Baylor Role:
Lead Sponsor
Completed
Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs). (External Link)
Participation in this study will be for one year. Patients will receive this treatment either while in hospital or in the outpatient clinic. Each patient will be entered into one …
Baylor Role:
Lead Sponsor
Completed
Treating Severe Chronic Epstein-Barr Virus (EBV) Infection With EBV Specific Cytotoxic T Lymphocytes (CTLs) (External Link)
Ten to sixty ml (2-12 teaspoons) of blood will be collected from the patient which we use to grow the T cells. These T cells are then stimulated with EBV …
Baylor Role:
Lead Sponsor
Completed
Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow Grafts (External Link)
We will obtain blood from the donor and will first make a B cell line called a lymphoblastoid cell line or LCL by infecting the blood with a laboratory strain …
Baylor Role:
Lead Sponsor